|
[1] WANG ZT,HU RH,XIONG Y. Progressoftreatmentonnon-alcoholicfattyliverdisease[J/CD]. Chin J Liver Dis(Electr Version),2018,10(4):48-53.(in Chinese)王中涛，胡荣华，熊勇．非酒精性脂肪性肝病治疗进展[J/CD]．中国肝脏病杂志(电子版)，2018,10(4):48-53.
|
|
[2] POVSIC M,WONG OY,PERRY R et al. A structured literature review of the epidemiology and disease burden of nonalcoholic steatohepatitis(NASH)[J]. Adv Ther,2019,36(42):1574-1594.
|
|
[3] BERG EHVD,DOUWES RM,MEIJER VED,et al. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity[J]. Dig Liver Dis,2018,50(1):68-75.
|
|
[4] LEI H,LINFENG D,QUAN Z,et al. Diagnostic value of CK-18,FGF-21,and related biomarker panel in nonalcoholic fatty liver disease:A systematic review and meta-analysis[J].Bio Med Res Int,2017,2017:1-12.
|
|
[5] SUZUKI A,ANGULO P,LYMP J,et al. Hyaluronic acid,an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease[J]. Liver Int,2010,25(4):779-786.
|
|
[6] WANG XX,LI XH,LIU F,et al. Progress in serum markers for non-alcoholic fatty liver disease[J]. Chin J Lab Med,2019,42(3):165-169.(in Chinese)王晓晓，李晓鹤，刘峰，等．非酒精性脂肪性肝病血清学检测进展[J]．中华检验医学杂志，2019,42(3):165-169.
|
|
[7] XIAO G,ZHU S,XIAO X,et al. Comparison of laboratory tests,ultrasound,or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease:A meta-analysis[J]. Hepatology,2017,66(5):1486-1501.
|
|
[8] ANGULO P,HUI JM,MARCHESINI G,et al. The NAFLD fibrosis score:A noninvasive system that identifies liver fibrosis in patients with NAFLD[J]. Hepatology,2007,45(4):846-854.
|
|
[9] MCPHERSON S,STEWART SF,HENDERSON E,et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J]. Gut,2010,59(9):1265-1269.
|
|
[10] MCPHERSON S,HARDY T,DUFOUR JF,et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis[J]. Am J Gastroenterol,2017,112(5):740-751.
|
|
[11] GUHA IN,PARKES J,RODERICK P,et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease:Validating the european liver fibrosis panel and exploring simple markers[J]. Hepatology,2008,47(2):455-460.
|
|
[12] BOURSIER J,DE LV,LEROY V,et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis[J]. J Hepatol,2017,66(6):1158-1165.
|
|
[13] TAPPER EB,CHALLIES T,NASSER I,et al. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease[J]. Am J Gastroenterol,2016,111(5):677-684.
|
|
[14] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.
|
|
[15] HONG J,SHI YW,WU XN,et al. Application value of imaging diagnosis in nonalcoholic fatty liver disease[J]. J Clin Hepatol,2018,34(12):2698-2701.(in Chinese)洪佳，施漪雯，吴晓宁，等．影像学诊断技术在非酒精性脂肪性肝病中的应用价值[J]．临床肝胆病杂志，2018,34(12):2698-2701.
|
|
[16] LIU H,FU J,HONG R,et al. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients:A systematic review&meta-analysis[J]. PLo S One,2015,10(7):e0127782.
|
|
[17] CASSINOTTO C,JROME B,VICTOR DE L,et al. Liver stiffness in nonalcoholic fatty liver disease:A comparison of supersonic shear imaging,FibroScan,and ARFI with liver biopsy[J]. Hepatology,2016,63(6):1817-1827.
|
|
[18] FLORES A,ASRANI SK. Editorial:Magnetic resonance elastography and non-alcoholic fatty liver disease:Time for an upgrade?[J]. Am J Gastroenterol,2016,111(7):995-996.
|
|
[19] BESUTTI G,VALENTI L,LIGABUE G,et al. Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients:A systematic review[J]. Liver Int,2019,39(8):1521-1534.
|
|
[20] HANG SX,SHEN HY,CHEN M. Correlation of serum SHGB levels with insulin sensitivity,lipid metabolism,oxidative stress in patients with nonalcoholic fatty liver disease[J]. J Clin Exp Med,2019,18(1):82-85.(in Chinese)杭双熊，申红玉，陈敏．非酒精性脂肪性肝病患者血清SHGB含量与胰岛素敏感性、脂代谢、氧化应激的相关性[J]．临床和实验医学杂志，2019,18(1):82-85.
|
|
[21] VILAR-GOMEZ E,YASELLS-GARCIA A,MARTINEZ-PEREZ Y,et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention[J]. Hepatology,2016,63(6):1875-1887.
|
|
[22] TANNAZ E,PUNEETA T,MAITREYI R. Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease[J]. Nutrients,2017,9(8):800.
|
|
[23] ROEB E,STEFFEN HM,BANTEL H,et al. S2k Guideline non-alcoholic fatty liver disease[J]. Z Gastroenterol,2015,53(7):668-723.
|
|
[24] PACANA T,SANYAL AJ. Vitamin E and nonalcoholic fatty liver disease[J]. Curr Opin Clin Nutr Metab Care,2012,15(6):641-648.
|
|
[25] GOLABI P,BUSH H,YOUNOSSI ZM. Treatment strategies for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Clin Liver Dis,2017,21(4):739-753.
|
|
[26] ZEIN CO,YERIAN LM,GOGATE P,et al. Pentoxifylline improves nonalcoholic steatohepatitis:A randomized placebocontrolled trial[J]. Hepatology,2011,54(5):1610-1619.
|
|
[27] LOOMBA R,LAWITZ E,MANTRY PS,et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis:A randomized,phase 2 trial[J]. Hepatology,2017,67(2):549-559.
|
|
[28] RATZIU V,HARRISON SA,FRANCQUE S,et al. Elafibranor,an agonist of the peroxisome proliferator-activated receptor-αand-δ，induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology,2016,150(5):1147-1159. e5.
|
|
[29] PAI V,PANEERSEIVAM A,MUKHOPADHYAY S,et al. A Multicenter,prospective,randomized,double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia(PRESS V)[J]. J Diabetes Sci Technol,2014,8(1):132-141.
|
|
[30] ARMSTRONG MJ,GAUNT P,AITHAL GP,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):A multicentre,double-blind,randomised,placebo-controlled phase 2 study[J]. Lancet,2016,387(10019):679-690.
|
|
[31] NEUSCHWANDERTETRI BA,LOOMBA R,SANYAL AJ,et al.Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic,non-alcoholic steatohepatitis(FLINT):A multicentre,randomised,placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.
|
|
[32] HARRISON SA,RINELLA ME,ABDELMALEK MF,et al. NGM282for treatment of non-alcoholic steatohepatitis:A multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet,2018,391(10126):1174-1185.
|
|
[33] LAWITZ EJ,COSTE A,POORDAD F,et al. Acetyl-Co A carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2018, 16(12):1983-1991.
|
|
[34] JIA H,RAO HY. Clinical trials tracking nonalcoholic fatty liver disease:Drug classification[J]. J Clin Hepatol,2018,34(12):2495-2500.(in Chinese)贾寒，饶慧瑛．跟踪非酒精性脂肪性肝病的临床试验-药物分类[J]．临床肝胆病杂志，2018,34(12):2495-2500.
|
|
[35] FRIEDMAN S,SANYAL A,GOODMAN Z,et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis:CENTAUR Phase 2b study design[J]. Contemp Clin Trials,2016,47:356-365.
|
|
[36] HE WW,AN XF,LI L,et al. Relationship between hypothyroidism and non-alcoholic fatty liver disease:A systematic review and Meta-analysis[J]. Front Endocrinol(Lausanne),2017,8:335.
|
|
[37] SAYINER M,LAM B,GOLABI P,et al. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis[J]. Ther Adv Gastroenterol,2018,11:1-12.
|
|
[38] HUNG CK,BODENHEIMER HC. Current treatment of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Clin Liver Dis,2018,22(1):175-187.
|
DownLoad: